0001437749-24-001061.txt : 20240110 0001437749-24-001061.hdr.sgml : 20240110 20240110073735 ACCESSION NUMBER: 0001437749-24-001061 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240107 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 24524876 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 8-K 1 tgtx20240109_8k.htm FORM 8-K tgtx20240109_8k.htm
false 0001001316 0001001316 2024-01-07 2024-01-07
 ​​


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

FORM 8-K
 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): January 7, 2024
 
TG Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-32639
36-3898269
(State or Other Jurisdiction
(Commission File Number)
(IRS Employer Identification No.)
of Incorporation)
 ​
3020 Carrington Mill Blvd, Suite 475
Morrisville, North Carolina 27560
(Address of Principal Executive Offices)
 
(212) 554-4484
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities filed pursuant to Section 12(b) of the Act:
 
Title of Class
Trading Symbol(s)
Exchange Name
Common Stock
TGTX
Nasdaq Capital Market
 ​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


 
 

 ​
Item 1.01. Entry into a Material Definitive Agreement.
 ​
On January 7, 2024, TG Therapeutics, Inc. (the “Company”) and its wholly-owned subsidiary, TG Cell Therapy, Inc., entered into a License Agreement (the “License Agreement”) with Precision BioSciences, Inc. (“Precision”), pursuant to which Precision granted the Company certain exclusive and non-exclusive license rights to develop, manufacture, and commercialize Precision’s allogeneic CAR T therapy azercabtagene zapreleucel (“azer-cel”) for the treatment of autoimmune and other non-oncology diseases and conditions (collectively, the “Field”).
 
Pursuant to the License Agreement, the Company will make an upfront payment to Precision of $7.5 million, consisting of (i) $5.25 million in cash and (ii) $2.25 million, as an equity investment, for the purchase of 2,920,816 shares of Precision’s common stock at a price of $0.77 per share. Within 12 months of the License Agreement, the Company will make a deferred payment of $2.5 million to Precision, consisting of an equity investment in Precision’s common stock at a 100% premium to the 30-day volume-weighted average price (the “30-day VWAP”) prior to purchase. Upon achievement of certain near-term clinical or time-based milestones, the Company will make a $7.5 million payment to Precision, a portion of which will also be an equity investment in Precision’s common stock at a 100% premium to the 30-day VWAP prior to purchase. Precision will be eligible to receive up to $288 million in additional milestone payments based on the achievement of certain clinical, regulatory, and commercial milestones. In addition, the Company is obligated to pay Precision high-single-digit to low-double-digit royalties on net sales of the licensed product on a country-by-country basis until the latest to occur of patent expiration, loss of regulatory exclusivity, and a period of ten years following the first commercial sale of the licensed product in such country. The Company has also agreed to make certain payments to Precision’s licensors during the term of the License Agreement.
 
Pursuant to the terms of the License Agreement, manufacturing for near-term clinical supply will be provided by a third party that recently acquired the manufacturing facility for azer-cel from Precision at a pre-determined cost.
 
The License Agreement also grants the Company a right of reference to the third party’s regulatory filings for the development of azer-cel in the Field. The Company must use commercially reasonable efforts to develop and commercialize azer-cel in the Field, including initiation of a Phase 1 clinical trial within a pre-specified timeframe following the effective date of the License Agreement.
 
Unless earlier terminated, the License Agreement will remain in effect on a licensed product-by-licensed product and country-by-country basis until the expiration of a defined royalty term for each licensed product and country. Precision may terminate the entire License Agreement if: (i) the Company brings a challenge to its patents brought or (ii) the Company ceases active development of azer-cel for a specified period of time. Either party may terminate the License Agreement (i) for material breach by the other party and a failure to cure such breach within the time period specified in the agreement or (ii) the other party’s insolvency.
 
The Company expects to file the Agreement as an exhibit to its Annual Report on Form 10-K for the year ended December 31, 2023. The foregoing is a description of certain terms of the Agreement and is intended to be a summary of the material terms and is qualified in its entirety by reference to the text of the Agreement when filed.
 
 

 
 
Item 7.01 Regulation FD Disclosure.
 
On January 10, 2024, the Company issued a press release entitled “TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones.”
 
For purposes of this Item 7.01, the Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01. Financial Statements and Exhibits.
     
Exhibit No.
 
Description
     
99.1
 
Exhibit 104
 
The cover page from this Current Report on Form 8-K formatted in Inline XBRL.
 ​
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
TG Therapeutics, Inc.
 
(Registrant)
 
Date: January 10, 2024
By:
/s/ Sean A. Power
 
 Sean A. Power
 
 Chief Financial Officer
 
 ​
 
EX-99.1 2 ex_613911.htm EXHIBIT 99.1 ex_613911.htm

Exhibit 99.1

 

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones

 

Preliminary U.S. BRIUMVI fourth quarter and full year 2023 net product revenue of approximately $40 million and $89 million, respectively

Preliminary year-end 2023 cash position of approximately $215 million

 

NEW YORK, January 10, 2024 -- TG Therapeutics, Inc. (NASDAQ: TGTX), yesterday announced preliminary U.S. net product revenue for BRIUMVI® for the fourth quarter and full year ended December 31, 2023 (unaudited), as well as financial guidance and development milestones for 2024, during a preannounced presentation at the 42nd Annual J.P Morgan Healthcare Conference. An audio replay of the event, as well as the corresponding slide deck are available on the Investors and Media section of the TG corporate website at ir.tgtherapeutics.com/events.

 

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics stated, “We are excited to share our preliminary fourth quarter and year end U.S. BRIUMIVI net product revenue. As we head into 2024, we have our sights set on achieving revenue and expense targets and have built an ambitious plan to potentially expand the utility of BRIUMVI into new indications and for use as a subcutaneous injection. We are also excited to expand our R&D program with the recent licensing of azer-cel, an allogeneic CD19 CAR T therapy which we believe has the potential to become a meaningful therapy to treat various autoimmune disorders.”

 

Preliminary Fourth Quarter and Full Year 2023 Updates (based on unaudited financial information)

 

 

BRIUMVI U.S. net product revenue expected to be approximately $40 million and $89 million for the fourth quarter and full year of 2023, respectively

 

Year-end 2023 cash position of approximately $215 million

 

Preliminary selected financial information presented in this release are unaudited, subject to financial closing procedures and adjustment, and provided as an approximation in advance of the Company's announcement of complete financial results planned to occur February 2024.

 

2024 Target Guidance

 

 

BRIUMVI U.S. net product revenue targets of approximately $41-$46 million and $220-$260 million for the first quarter and full year 2024, respectively

 

Full year 2024 target operating expense of approximately $250 million

 

2024 Development Pipeline Anticipated Milestones

 

 

Commence clinical development of subcutaneous BRIUMVI

 

Commence a trial evaluating BRIUMVI in additional autoimmune diseases outside of Multiple Sclerosis (MS)

 

Commence a trial evaluating azer-cel in autoimmune disease

 

Present data from the ENHANCE Phase 3b CD20 switch trial at multiple conferences throughout the year

 

 

 

ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as relapsing forms of multiple sclerosis (RMS). BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.

BRIUMVI is indicated for the treatment of adults with RMS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

 

A list of authorized specialty distributors can be found at www.briumvi.com.

 

IMPORTANT SAFETY INFORMATION

Contraindications: BRIUMVI is contraindicated in patients with:

Active Hepatitis B Virus infection

A history of life-threatening infusion reaction to BRIUMVI

 

WARNINGS AND PRECAUTIONS

 

Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization.

 

Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.

 

Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI-treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved.

 

Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.

 

Hepatitis B Virus (HBV) Reactivation: HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HBsAg and anti-HB tests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.

 

Progressive Multifocal Leukoencephalopathy (PML): Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies.

 

If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

 

 

 

MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.

 

If PML is confirmed, treatment with BRIUMVI should be discontinued.

 

Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.

 

Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy: In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.

 

Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is recommended in females of reproductive potential prior to each infusion. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.

 

Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

 

Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections.

 

Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit www.briumvi.com.

The full SmPC approved in the EU for BRIUMVI can be found here Briumvi | European Medicines Agency (europa.eu).

 

 

ABOUT BRIUMVI PATIENT SUPPORT in the U.S.
BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at www.briumvipatientsupport.com.


ABOUT MULTIPLE SCLEROSIS
Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately 85% are initially diagnosed with RRMS.1,2 The majority of people who are diagnosed with RRMS will eventually transition to SPMS, in which they experience steadily worsening disability over time. Worldwide, more than 2.3 million people have a diagnosis of MS.1

 

 

 

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

 

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

 

Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

 

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.

 

Such forward looking statements include but are not limited to statements regarding expectations for success of our commercial launch and availability of BRIUMVI® (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS); and anticipated healthcare professional and patient acceptance and use of BRIUMVI for the FDA-approved indications, expectations of future revenue for BRIUMVI, expenses or profits, and our statements regarding our potential revenue targets, operating expenses and cash position.

 

Additional factors that could cause our actual results to differ materially include the following: the Company’s ability to establish and maintain a commercial infrastructure for BRIUMVI, and to successfully or in the timeframe projected, market and sell BRIUMVI; the risk that early trends in prescriptions are not maintained or that prescriptions are not filled; the failure to obtain and maintain payor coverage; the risk that early healthcare professional interest in BRIUMVI will not be sustained; the risk that momentum in sales for BRIUMVI will not build during the course of the year; the risk that the BRIUMVI launch does not continue to exceed expectations; the risk that our BRIUMVI revenue targets will not be achieved; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements, the potential for variation from the Company’s projections and estimates about the potential market for BRIUMVI due to a number of factors, including, further limitations that regulators may impose on the required labeling for BRIUMVI (such as modifications, resulting from safety signals that arise in the post-marketing setting or in the long-term extension study from the ULTIMATE I and II clinical trials); the Company’s ability to meet post-approval compliance obligations (on topics including but not limited to product quality, product distribution and supply chain, pharmacovigilance, and sales and marketing); the Company’s reliance on third parties for manufacturing, distribution and supply, and other support functions for our clinical and commercial products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; potential regulatory challenges to the Company’s plans to seek marketing approval for the product in jurisdictions outside of the U.S.; the uncertainties inherent in research and development; the risk that any individual patient’s clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials such as ULTIMATE I and II; the risk that subcutaneous BRIUMVI does not exhibit favorable safety, efficacy, or pharmacokinetic properties when evaluated in humans; the risk that the safety or tolerability profile of BRIUMVI differs in other autoimmune disorders compared to what has been observed in patients with MS; the risk that the Company is delayed in initiating a clinical trial for azer-cel in non-oncology indications; and general political, economic and business conditions, including the risk that the ongoing COVID-19 pandemic could have on the safety profile of BRIUMVI and any of our other drug candidates as well as any government control measures associated with COVID-19 that could have an adverse impact on our research and development plans or commercialization efforts. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in our other filings with the U.S. Securities and Exchange Commission.

 

 

 

Any forward-looking statements set forth in this press release speak only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.


CONTACT:

 

Investor Relations

Email: ir@tgtxinc.com

Telephone: 1.877.575.TGTX (8489), Option 4

 

Media Relations:

Email: media@tgtxinc.com

Telephone: 1.877.575.TGTX (8489), Option 6

 

 

1. MS Prevalence. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Datamonitor p. 236.

 

 
EX-101.SCH 3 tgtx-20240107.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 tgtx-20240107_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 tgtx-20240107_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 tgtx-20240107_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document And Entity Information
Jan. 07, 2024
Document Information [Line Items]  
Entity, Registrant Name TG Therapeutics, Inc.
Document, Type 8-K
Document, Period End Date Jan. 07, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-32639
Entity, Tax Identification Number 36-3898269
Entity, Address, Address Line One 3020 Carrington Mill Blvd, Suite 475
Entity, Address, City or Town Morrisville
Entity, Address, State or Province NC
Entity, Address, Postal Zip Code 27560
City Area Code 212
Local Phone Number 554-4484
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol TGTX
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001001316
XML 8 tgtx20240109_8k_htm.xml IDEA: XBRL DOCUMENT 0001001316 2024-01-07 2024-01-07 false 0001001316 8-K 2024-01-07 TG Therapeutics, Inc. DE 001-32639 36-3898269 3020 Carrington Mill Blvd, Suite 475 Morrisville NC 27560 212 554-4484 false false false false Common Stock TGTX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.tgtx.com/20240107/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports tgtx-20240107.xsd tgtx-20240107_def.xml tgtx-20240107_lab.xml tgtx-20240107_pre.xml tgtx20240109_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tgtx20240109_8k.htm": { "nsprefix": "tgtx", "nsuri": "http://www.tgtx.com/20240107", "dts": { "schema": { "local": [ "tgtx-20240107.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "tgtx-20240107_def.xml" ] }, "labelLink": { "local": [ "tgtx-20240107_lab.xml" ] }, "presentationLink": { "local": [ "tgtx-20240107_pre.xml" ] }, "inline": { "local": [ "tgtx20240109_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.tgtx.com/20240107/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "tgtx20240109_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "tgtx20240109_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tgtx.com/20240107/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001437749-24-001061-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-001061-xbrl.zip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end